


# Appendix

**Appendix 1.** Funnel plots. **A**, Cystoid macular edema occurrence rate at three months. **B**, Cystoid macular edema occurrence rate among anti-VEGF trials at one month. **C**, Best corrected visual acuity at three months. **D**, Best corrected visual acuity among anti-VEGF trials at one month.





**Appendix 2.** Risk of bias assessment with ROB2. D1: Randomization, D2: Deviations from the intended interventions, D3: Missing data, D4: Measurement, D5: Selection report. (SC: Some Concern.)

Study	D1	D2	D3	D4	D5	Overall
Fard 2010	SC <sup>1</sup>	Low	Low	Low	Low	SC
Chae 2014	SC <sup>1</sup>	Low	Low	Low	Low	SC
Khodabandeh 2018	SC <sup>1</sup>	Low	Low	Low	Low	SC
Song 2020	SC <sup>1</sup>	Low	Low	Low	Low	SC
Entezari 2016	SC <sup>1</sup>	Low	Low	Low	Low	SC
Pollack 2016	Low	Low	Low	Low	Low	Low
Singh 2017A	SC <sup>1</sup>	Low	Low	Low	Low	SC
Singh 2017B	SC <sup>1</sup>	Low	Low	Low	Low	SC

<sup>1</sup>: Randomization process might have been revealed to researcher before the allocation.

**Appendix 3.** Net graph of conducted network meta-analysis. **A**, Occurrence of Cystoid Macular Edema at 3 Months. **B**, Best Corrected Visual Acuity at 3 Months.



**Appendix 4.** Baujat Diagnostics. **A**, Occurrence of Cystoid Macular Edema of NSAID Group at 3 Months. **B**, Best Corrected Visual Acuity of Anti-VEGF Group at One Month.

**A**

Omitting	Heterogeneity Contribution	Influence Effect Size
Fard 2010	3.871	1.193
Chae 2014	1.643	0.818
Song 2020	0.933	0.141
Khodabandeh 2018	0.06	0.026

**B**

Omitting	Heterogeneity Contribution	Influence Effect Size
Singh 2017A	3.380	1.193
Singh 2017B	1.402	0.818
Pollack 2016	0.009	0.207

**Appendix 5.** Egger's test results

Macular edema occurrence rate		BCVA mean change	
P-Value		P-Value	
NSAID			
Three months	0.653	Not applicable	
Anti-VEGF			
One month	0.827	0.958	
Three months	0.489	0.651	

**Appendix 6.** Complete search terms.

“(Diabetes Mellitus OR Diabetic Retinopathy OR Macular Edema) AND (Cataract Extraction OR Phacoemulsification) AND (((Bevacizumab) OR Ranibizumab) OR Aflibercept) OR Anti-Inflammatory Agents, Non-Steroidal)”